**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 74437

**Manuscript Type:** CASE REPORT

**Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report**

Zhang N *et al*. Development of plasma cell dyscrasias in chronic myeloid leukemia

Na Zhang, Ting-De Jiang, Shu-Hua Yi

**Na Zhang, Ting-De Jiang,** Department of Hematology, People’s Hospital of Deyang, Deyang 618000, Sichuan Province, China

**Shu-Hua Yi,** Hematology Hospital of the Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin 300020, China

**Author contributions:** Zhang N, Jiang TD and Yi SH designed and wrote this manuscript; Zhang N revised the manuscript; all authors reviewed and approved the final version to be published.

**Corresponding author: Shu-Hua Yi, MD, Attending Doctor,** Hematology Hospital of the Institute of Hematology, Chinese Academy of Medical Sciences, No. 288 Nanjing Road, Tianjin 300020, China. 3378465425@qq.com

**Received:** December 23, 2021

**Revised:** February 21, 2022

**Accepted:** March 17, 2022

**Published online:** May 16, 2022

**Abstract**

BACKGROUND

Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder. Plasma cell dyscrasias are a rare heterogeneous group of hematological disorders. The co-occurrence of CML and plasma cell dyscrasias in the same patient is an extremely rare incident and has been reported in several cases in the literature.

CASE SUMMARY

In the present report, we described a rare case of the co-occurrence of CML and plasma cell dyscrasias in a 48-year-old man, and we discussed the reason why monoclonal gammopathy of undetermined significance progressed to smoldering multiple myeloma and eventually to multiple myeloma while being treated with dasatinib for CML. The tyrosine kinase inhibitor treatment and cytogenetic change may contribute to this phenomenon, and clonal hematopoiesis of indeterminate potential may lead to both CML and multiple myeloma cells in a patient. Future studies are warranted to further explain the hidden reasons.

CONCLUSION

This case highlights that gene translocation may contribute to initiation and sustainability of clonal proliferation. Moreover, the treatment with tyrosine kinase inhibitor and cytogenetic change may contribute to progression from monoclonal gammopathy of undetermined significance to smoldering multiple myeloma and eventually to multiple myeloma.

**Key Words:** Chronic myeloid leukemia; Plasma cell dyscrasias; Multiple myeloma; Tyrosine kinase inhibitor; Translocation; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhang N, Jiang TD, Yi SH. Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report. *World J Clin Cases* 2022; 10(14): 4698-4703

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i14/4698.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i14.4698

**Core Tip:** Here we describe a patient with chronic myeloid leukemia complicated with plasma cell dyscrasias receiving dasatinib. He developed monoclonal gammopathy of undetermined significance that progressed to smoldering multiple myeloma and eventually to multiple myeloma. This case highlights that gene translocation may contribute to initiating and sustaining clonal proliferation. Tyrosine kinase inhibitors and cytogenetic change may lead to the progression.

**INTRODUCTION**

Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder, which is defined by the presence of Philadelphia chromosome in a patient with a myeloproliferative neoplasm. Plasma cell dyscrasias (PCD) are a rare heterogeneous group of hematological disorders, which include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM), systemic amyloid light chain amyloidosis, and polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome, *etc*[1,2]. MGUS is an asymptomatic, premalignant disorder characterized by monoclonal plasma cell proliferation in the bone marrow and absence of end-organ damage such as osteolytic bone lesions, anemia, or renal failure[3]. It shows the risk of progression to MM and associated plasma cell neoplasms[4]. MM arises from the malignant transformation of post-germinal center plasma cells. The origin of the cells is distinctly different in CML and PCD. There were several cases of coexistence of CML and MM. However, there was few distinctive report about the evolution from MGUS to smoldering multiple myeloma (SMM) and to MM in patients with CML complicated with PCD. In this case report, we described a patient who developed MGUS that progressed to SMM and eventually to MM while being treated with dasatinib for CML. The tyrosine kinase inhibitor (TKI) treatment and cytogenetic change may contribute to this phenomenon.

**CASE PRESENTATION**

***Chief complaints***

A 48-year-old man who was admitted to our hospital was diagnosed with leukocytosis with white blood cell count of 25.2 × 109/L, hemoglobin level of 149 g/L, platelet count of 330 × 109/L, eosinophils level of 0.99 × 109/L, and basophil level of 1.38 × 109/L without any complaints during the health examination.

***History of present illness***

No special physical signs and symptoms were reported before. He did not appear to have a history of exposure to toxic agents or irradiation.

***History of past illness***

The patient did not have previous medical history.

***Physical examination***

No other special physical signs.

***Laboratory examinations***

At first, his serum creatinine was 110.18 μmol/L. His lactate dehydrogenase was 364.04 U/L. His total protein and albumin were normal. His 24-h urine for total protein was 1.82 g/24 h. His serum immunofixation electrophoresis was weakly positive. Quantitative reverse transcription PCR using international scale for BCR/ABLP210 (blood) was 48.02%. The bone marrow plasma cells percentage was 1%. The diagnosis of CML was confirmed by quantitative PCR analysis 4 mo after he received dasatinib.

In December 2020, fluorescence *in situ* hybridization (FISH) for t(9;22) (q34;q11) was negative and BCR/ABL transcript has decreased from 48.02% to 0.25%. Then the percentage of bone marrow mature plasma cells was 4%. Serum free light chain ratio (κ/λ) was 85.62.

In March 2021, his BCR/ABL transcript was 0.06% and rFLC (κ-FLC:λFLC) was 93.56%. Serum immunofixation electrophoresis and serum protein electrophoresis were negative. M1-protein in urine protein electrophoresis was 89.99%. Urine immunofixation electrophoresis revealed the presence of monoclonal light chain κ. The percentage of plasma cells in bone marrow was about 11.5% (Figure 1). Whole-body low-dose computed tomography scan documented no osteolytic lesions.

In April 2021, his BCR/ABL transcript was 0. At this time, serum immunofixation electrophoresis showed monoclonal light chain κ, but serum protein electrophoresis was still negative, and rFLC (κ-FLC:λ-FLC) was 144.43. The 24-h urine for total protein rose to 3.84 g/24 h. M1-protein in urine protein electrophoresis was 88.47%. Cytogenetic karyotyping results revealed normal male chromosome complement.

***Imaging examinations***

FISH analysis for the immunoglobulin heavy chain locus on chromosome 14q32 was positive (Figure 2A and B). FISH analysis for RB-1/LAMP1 showed deletion of chromosome 13q14 (Figure 2C and D). Another FISH analysis was normal for immunoglobulin heavy chain partner gene arrangement, CKS1B/CDKN2C and P53/CEP17.

**FINAL DIAGNOSIS**

The final diagnosis for the present case was the coexistence of CML and MM.

**TREATMENT**

Now he is receiving bortezomib, lenalidomide, and dexamethasone chemotherapy with simultaneously continued oral dasatinib. After 4 to 6 cycles of bortezomib, lenalidomide, and dexamethasone treatment when he achieves complete response, he will receive an allogeneic hematopoietic stem cell transplantation.

**OUTCOME AND FOLLOW-UP**

He has finished six cycles of chemotherapy with bortezomib, lenalidomide, and dexamethasone, and he has already completed a pretransplant match. In 1 mo, he will receive an allogeneic transplant.

**DISCUSSION**

CML is a clonal myeloproliferative neoplasm derived from an abnormal multipotent hemopoietic stem cell that has acquired the BCR-ABL1 fusion gene, usually through t(9;22) (q34;q11), also known as the Philadelphia chromosome. The derivation of this clonal population from a multipotent hematopoietic stem cell was supported by cytogenetic studies[5]. In rare cases, BCR-ABL1 has been described in essential thrombocytosis, myelodysplastic syndrome, MM, and malignant lymphoma.

MGUS is a clinically asymptomatic premalignant clonal plasma cell. Smoldering myeloma describes a stage of disease that has no symptoms and no related organ or tissue impairment.

In this case, the patient was diagnosed with CML initially, and 4 mo later was confirmed with a diagnosis of MGUS, which ultimately progressed to MM. The hypothesis is that CML and MGUS can occur simultaneously because of elevated serum light chain at the time of diagnosis of CML. Regrettably, no further examination was carried out at that time to verify the simultaneous occurrence of CML and MGUS.

The cause of coexistence of CML and PCD in 1 patient remains unclear. The paramount etiology may be what precursors commonly referred to as “clonal hematopoiesis of indeterminate potential” leads to both CML and MM cells in a patient[6]. Clonal hematopoiesis is often detected by next-generation sequencing, chromosomal analysis, FISH analysis, PCR, and other techniques. Dysplasia and blasts were not discovered in bone marrow in the early stage of the disease, which could not verify the pathogenesis. Meanwhile a new study also showed that all patients with myeloma go through the stage of MGUS, but it is often unrecognized for some reason or it is subclinical[7].

Another hypothesis is secondary malignancies related to TKI treatment of CML. Gunnarsson *et al*[8] studied 868 patients diagnosed with CML in Sweden in 2002, and results indicated that CML patients had a high risk of developing a second malignancy in the TKI era. The common malignancies include the following: gastrointestinal cancer, nose and throat cancer, prostate cancer, and breast cancer but not hematological cancer. However, whether the cause leading to a secondary malignancy is associated with TKI treatment or CML disease itself is uncertain. After all, multiple studies displayed that secondary cancers in CML were often found in early stage after the diagnosis of CML. The higher immunosuppressive effects and the DNA repair mechanisms of TKI may be involved in the phenomenon. For CML disease itself, BCR/ABL also participates in regulating cell apoptosis, proliferation, and intercellular interactions and promotes genomic instability, *etc*. Therefore, both the TKI treatment and CML disease itself may play an important role in the coexistence of CML and PCD in our case[8,9].

Studies show that the rate of progression from MGUS to MM is 1% per year but approximately 10% per year for SMM[10]. We want to know more about how this patient progressed from MGUS to SMM and then to MM under the circumstances of CML. Gene translocation may contribute to initiating and sustaining clonal proliferation. The common translocation at 14q32 and deletion of 13 in normal cells promote the genomic instability that results in the occurrence of MGUS/SMM. Finally, mutations in *RAS* genes, p16 methylation, abnormalities involving myc family of oncogenes, secondary translocations, p53 mutations, and angiogenesis play an important role in promoting the development of MGUS/SMM into MM. In addition to that, a higher serum free light chain ratio has been shown recently to be an important risk factor for the progression[3]. In this case, translocations at 14q32 and deletion of 13 in the patient was probably associated with the progression to MM.

**CONCLUSION**

Reports of the co-occurrence of CML and PCD in the same patient are rare. In the present report, we described a patient with CML. He received chemotherapy and oral dasatinib as therapy. During the follow-up, he developed MGUS and progressed to SMM and eventually to MM. Finally, the patient was diagnosed with CML and MM. TKI and cytogenetic change are thought to potentially contribute to his disease progression. Further studies should be made to better understand the etiology of the coexistence of CML and PCD.

**REFERENCES**

1 **Gavriatopoulou M**, Fotiou D, Ntanasis-Stathopoulos I, Kastritis E, Terpos E, Dimopoulos MA. How I treat elderly patients with plasma cell dyscrasias. *Aging (Albany NY)* 2018; **10**: 4248-4268 [PMID: 30568029 DOI: 10.18632/aging.101707]

2 **Gavriatopoulou M**, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. *Leukemia* 2018; **32**: 1883-1898 [PMID: 30038381 DOI: 10.1038/s41375-018-0209-7]

3 **Rajkumar SV**. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. *Hematology Am Soc Hematol Educ Program* 2005: 340-345 [PMID: 16304401 DOI: 10.1182/asheducation-2005.1.340]

4 **Ouyang W**, Zhao X, Lu S, Wang Z. Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report. *Medicine (Baltimore)* 2018; **97**: e13103 [PMID: 30383696 DOI: 10.1097/MD.0000000000013103]

5 **Whang J**, Frei E 3rd, Tjio JH, Carbone PP, Brecher G. The distribution of the Philadelphia chromosome in patients with chronic myelogenous leukemia. *Blood* 1963; **22**: 664-673 [PMID: 14084628]

6 **Miki K**, Obara N, Makishima K, Sakamoto T, Kusakabe M, Kato T, Kurita N, Nishikii H, Yokoyama Y, Sakata-Yanagimoto M, Hasegawa Y, Chiba S. An Unprecedented Case of p190 *BCR-ABL* Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature. *Case Rep Hematol* 2018; **2018**: 7863943 [PMID: 30405922 DOI: 10.1155/2018/7863943]

7 **Boyle EM**, Davies FE, Leleu X, Morgan GJ. Understanding the multiple biological aspects leading to myeloma. *Haematologica* 2014; **99**: 605-612 [PMID: 24688108 DOI: 10.3324/haematol.2013.097907]

8 **Gunnarsson N**, Stenke L, Höglund M, Sandin F, Björkholm M, Dreimane A, Lambe M, Markevärn B, Olsson-Strömberg U, Richter J, Wadenvik H, Wallvik J, Själander A. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. *Br J Haematol* 2015; **169**: 683-688 [PMID: 25817799 DOI: 10.1111/bjh.13346]

9 **Kumar V**, Garg M, Chaudhary N, Chandra AB. An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States. *PeerJ* 2018; **6**: e4342 [PMID: 29456888 DOI: 10.7717/peerj.4342]

10 **Ide M**, Kuwahara N, Matsuishi E, Kimura S, Gondo H. Uncommon case of chronic myeloid leukemia with multiple myeloma. *Int J Hematol* 2010; **91**: 699-704 [PMID: 20352382 DOI: 10.1007/s12185-010-0546-4]

**Footnotes**

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declared no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 23, 2021

**First decision:** January 25, 2022

**Article in press:** March 17, 2022

**Specialty type:** Hematology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Ikeda HO, Japan; Imanse SM, United States **S-Editor:** Wang JL **L-Editor:** Filipodia **P-Editor:** Wang JL

**Figure Legends**



**Figure 1 Wright Giemsa stain.** Bone marrow aspirate in the patient with multiple myeloma illustrated a preponderance of mostly mature-appearing plasma cells constituting 11.5% of the cells.



**Figure 2 Interphase fluorescence *in situ* hybridization analysis.** A: Interphase fluorescence *in situ* hybridization analysis for the immunoglobulin heavy chain locus on chromosome 14q32. Normal reference; B: 14q32 deletion with only one red signal; C: Interphase fluorescence *in situ* hybridization analysis. Normal reference; D: Monosomy of chromosome 13 with only one red and one green signal.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**